Carlsbad, CA, United States of America

Rosanne M Crooke

This inventor holds 52 USPTO granted patents and 32 published patent applications, plus 2 CIPO patents and 19 EPO patents, primarily in Lipid Modulation (CPC class C12N). Top assignees: Isis Pharmaceuticals, Inc., Ionis Pharmaceuticals, Inc., Genzyme Corporation. Active years: 2004-2023.

IDiyas Innovation Intelligence. (2026). Inventor Profile: Rosanne M Crooke. Retrieved from https://idiyas.com/inventor/rosanne-m-crooke

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

USPTO Granted Patents = 52 

% Patents Active = 53.8

 

 

Average Co-Inventor Count = 2.9

ph-index = 18

Forward Citations = 1,409(Granted Patents)

Forward Citations (Not Self Cited) = 1,318(Dec 10, 2025)


Inventors with similar research interests:


Company Filing History:


Years Active: 2004-2023

Loading Chart...
Loading Chart...
Loading Chart...
Areas of Expertise:
Apolipoprotein A
Apolipoprotein B
Apolipoprotein C-III
Angiopoietin-Like 3
Hypercholesterolemia
C-Reactive Protein
Antisense Modulation
Lipid Metabolism
Diabetic Profile
Gene Expression
Compositions
Methods
52 patents (USPTO):Explore Patents

Title: Innovations and Contributions of Rosanne M. Crooke

Introduction

Rosanne M. Crooke, based in Carlsbad, CA, is a prominent inventor with a remarkable portfolio of 52 patents. Her work primarily focuses on developing antisense compounds and methods that address critical health issues related to cardiovascular and metabolic diseases.

Latest Patents

Among her latest innovations are methods and compositions for modulating apolipoprotein (a) expression. These patents disclose antisense compounds and techniques aimed at decreasing apo(a) levels, targeting various diseases and disorders associated with apo(a) or Lp(a), including inflammatory, cardiovascular, and metabolic conditions. Additionally, she has developed methods for treating hypercholesterolemia, introducing antisense compounds that lower LDL-C in patients and reduce risk factors associated with coronary heart disease. The patented compounds often include gapmer antisense oligonucleotides specifically targeting PCSK9 nucleic acids.

Career Highlights

Rosanne has had a notable career, working with revered companies such as Isis Pharmaceuticals, Inc. and Ionis Pharmaceuticals, Inc. Her contributions to medicinal research and drug development have significantly propelled advancements in the treatment of critical health conditions.

Collaborations

Throughout her career, Rosanne has collaborated with esteemed colleagues, including Mark J. Graham and Susan M. Freier. These partnerships have fostered innovative solutions in the field of therapeutic research and development, further expanding the potential impact of her work.

Conclusion

With a prolific output of patents and a strong focus on improving health through innovative compounds, Rosanne M. Crooke continues to be a significant figure in the landscape of biomedical research. Her pioneering work will likely have lasting effects on the treatment of diseases, offering hope for many individuals in need of effective therapies.

Profile summary based on public USPTO records.
Data Sources: USPTO Patent Grant XML, Patent Center, EPO & CIPO • Normalized by IDiyas Innovation Graph. Methodology & provenance architecturePlease report any incorrect information to [email protected]
Loading…